Vox Biomedical Launches an Artificial Intelligence-based Cheminformatics Program
Industry: Healthcare
New AI library will expedite the discovery and confirmation of biomarkers for early-stage disease detection.
Bedford, MA (PRUnderground) June 13th, 2023
Warning: strpos(): Empty needle in /home/dev/public_html/wp-content/themes/pru2.0/functions.php on line 363
Vox Biomedical announced that it has received a program from the National Institute of General Medical Sciences (NIGMS) to develop an artificial intelligence based chemical identification library, for the identification of volatile organic compounds (VOCs), using a gas chromatography and differential mobility spectrometry (GC-DMS) technique.
Vox Biomedical scientists will utilize multi-task and deep neural network models to predict characteristics of a previously unseen analyte.
The development of Vox Biomedical’s Machine Learning (ML) based library, called ML-VOX1, promises to streamline the process of identifying complex spectral signatures and improve the accuracy of Vox Biomedical’s breath analyzer technology.
Vox Biomedical is currently developing a GC-DMS based breath analyzer system (VenturiTM) for detecting the presence of psychoactive drugs and diseases through exhaled breath analysis.
The creation of proprietary chemical identity library based on Artificial Intelligence (AI) would result to make biomarker discovery for disease a less resource intensive process expediting the discovery and confirmation of biomarkers for early-stage disease detection, ultimately saving lives.
Disclaimer: Research reported in this press release is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R43GM149051. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Contact:
Arash Aslani
VP/GM
781-301-3893
info@voxbiomedical.com